drugset / Trial / NCT02479022

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects

NCT02479022

Phase 1 Completed 84 enrolled Novo Nordisk A/S
RandomizedSingle-groupDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of insulin 320 in healthy subjects.

Timeline

Start
2015-06
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin 320 Unknown 300 unknown Oral
Subject Insulin 320 Unknown 21600 unknown Oral
Subject insulin glargine Protein / enzyme biologic Subcutaneous